| Patient characteristics before PSW | Patient characteristics (%) after PSWa | ||||
---|---|---|---|---|---|---|
CCT (n = 103) | Without CCT (n = 265) | Standardized differenceb | CCT | Without CCT | Standardized differenceb | |
Number (%)b or mean (SD)b | Number (%)b or mean (SD)b | |||||
Age (years) | Â | Â | Â | Â | Â | Â |
  ≤ 58 | 53 (51) | 139 (52) | 0.020 | 50 | 50 | ≈ 0 |
  > 58 | 50 (49) | 126 (48) |  | 50 | 50 |  |
Gender | Â | Â | Â | Â | Â | Â |
 Female | 5 (5) | 12 (5) | 0.015 | 5 | 5 | ≈ 0 |
 Male | 98 (95) | 253 (95) |  | 95 | 95 |  |
Residency | Â | Â | Â | Â | Â | Â |
 Non-north | 77 (75) | 185 (70) | 0.111 | 73 | 73 | ≈ 0 |
 North | 26 (25) | 80 (30) |  | 27 | 27 |  |
Comorbidity | Â | Â | Â | Â | Â | Â |
 Without | 91 (88) | 233 (88) | 0.013 | 89 | 89 | ≈ 0 |
 Withc | 12 (12) | 32 (12) |  | 11 | 11 |  |
BMI (kg/m2) | Â | Â | Â | Â | Â | Â |
  ≤ 18.5 | 22 (21) | 62 (23) | 0.049 | 21 | 21 | ≈ 0 |
  > 18.5 | 81 (79) | 203 (77) |  | 79 | 79 |  |
Drinking | Â | Â | Â | Â | Â | Â |
 No | 14 (14) | 46 (17) | 0.104 | 14 | 14 | ≈ 0 |
 Yes | 89 (86) | 219 (83) |  | 86 | 86 |  |
Smoking | Â | Â | Â | Â | Â | Â |
 No | 10 (10) | 43 (16) | 0.195 | 11 | 11 | ≈ 0 |
 Yes | 93 (90) | 222 (84) |  | 89 | 89 |  |
Grade | Â | Â | Â | Â | Â | Â |
 Poorly | 34 (33) | 59 (22) | 0.242 | 30 | 30 | ≈ 0 |
 Well/moderately differentiated | 69 (67) | 206 (78) |  | 70 | 70 |  |
Tumor location | Â | Â | Â | Â | Â | Â |
 Upper | 56 (54) | 97 (37) |  | 50 | 50 |  |
 Middle | 34 (33) | 122 (46) | 0.269 | 36 | 36 | ≈ 0 |
 Lower | 13 (13) | 46 (17) | 0.133 | 14 | 14 | ≈ 0 |
Tumor size (cm) | Â | Â | Â | Â | Â | Â |
  ≤ 5 cm | 43 (42) | 99 (37) | 0.090 | 41 | 41 | ≈ 0 |
  > 5 cm | 60 (58) | 166 (63) |  | 59 | 59 |  |
Clinical T-stage | Â | Â | Â | Â | Â | Â |
 T1–T2 | 10 (10) | 32 (12) | 0.076 | 10 | 10 | ≈ 0 |
 T3–T4 | 93 (90) | 233 (88) |  | 90 | 90 |  |
Clinical N-stage | Â | Â | Â | Â | Â | Â |
 N0 | 9 (9) | 23 (9) | 0.002 | 9 | 9 | ≈ 0 |
 N1-N2 | 94 (91) | 242 (91) |  | 91 | 91 |  |
Clinical stage | Â | Â | Â | Â | Â | Â |
 II | 11 (11) | 30 (11) | 0.020 | 12 | 12 | ≈ 0 |
 III | 92 (89) | 235 (89) |  | 88 | 88 |  |
Reason for no surgery | Â | Â | Â | Â | Â | Â |
 Without contraindication | 99 (96) | 248 (94) | 0.115 | 95 | 95 | ≈ 0 |
 With contraindication | 4 (4) | 17 (6) |  | 5 | 5 |  |
RT modality | Â | Â | Â | Â | Â | Â |
 3DCRT | 7 (7) | 7 (3) | 0.197 | 5 | 5 | ≈ 0 |
 IMRT | 96 (93) | 258 (97) |  | 95 | 95 |  |
Use of PET | Â | Â | Â | Â | Â | Â |
 No | 45 (44) | 77 (29) | 0.308 | 37 | 37 | ≈ 0 |
 Yes | 58 (56) | 188 (71) |  | 63 | 63 |  |
RT break | Â | Â | Â | Â | Â | Â |
  ≤ 1 week | 79 (77) | 197 (74) | 0.055 | 76 | 76 | ≈ 0 |
  > 1 week | 24 (23) | 68 (26) |  | 24 | 24 |  |
RT dose | Â | Â | Â | Â | Â | Â |
 Low | 25 (24) | 88 (33) | 0.198 | 26 | 26 | ≈ 0 |
 High | 78 (76) | 177 (67) |  | 74 | 74 |  |
Induction chemotherapy | Â | Â | Â | Â | Â | Â |
 Without | 98 (95) | 258 (97) | 0.117 | 96 | 96 | ≈ 0 |
 With | 5 (5) | 7 (3) |  | 4 | 4 |  |